– USA, MA – Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointments of Olivier Brandicourt and Jürgen Eckhardt to its board of directors.
“We are thrilled to welcome Olivier and Jürgen to the board and feel lucky for the chance to tap their vast industry experience,” said CEO Amir Nashat. “We founded Dewpoint with the conviction that the company’s breakthrough insights into cell biology will impact all of drug discovery, and these new board additions validate that promise and the progress the platform has shown.”
About Olivier Brandicourt
An accomplished pharmaceutical industry leader, Dr. Brandicourt has served as CEO of both Sanofi S.A. and Bayer HealthCare AG. Prior to that, he held a series of leadership roles at Pfizer Inc., including a stint as President and General Manager of the Emerging Markets and Established Products units.
“It’s exciting to work with a company that is building on recent scientific insights to discover potential new therapies for diseases with large unmet medical needs,” said Dr. Brandicourt. “Scientists have long known about the existence of biomolecular condensates, but have only recently begun to understand how they play a role in the mechanism of disease. Dewpoint is the first to pioneer a new approach to drug development informed by this understanding.”
About Jürgen Eckhardt
A veteran biopharmaceutical investor, Dr. Eckhardt is SVP and Head of Leaps by Bayer, the impact investment unit of Bayer AG that utilizes venture capital in order to advance breakthrough technologies and disruptive business models in healthcare and agriculture. He serves on the boards of several innovative biotechnology companies.
“I have been impressed with Dewpoint since Leaps by Bayer participated, along with other top investors, in its Series A financing round,” said Dr. Eckhardt. “It has been exciting to see the company build its platform, launch its programs, and forge a collaboration with Bayer to bring potentially game-changing condensate technology to life.”
About Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates — including cancer, neurodegeneration, and metabolic disease. Dewpoint scientists are working in Boston, MA, and Dresden and Berlin, Germany, to translate condensate biology into treatments for the toughest diseases.
For more information: https://dewpointx.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
